Information Library

Results for: Faster product development - High-quality studies - Late Phase

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Quintiles Strengthens Late Phase Offerings with Acquisition of Outcome Sciences, Inc.

    Press Release — October 19, 2011 – With late phase (Phase IIIB and Phase IV) research becoming increasingly important to multiple healthcare stakeholders, Quintiles has acquired Outcome Sciences, Inc. (Outcome).

  • Quintiles Approach to "Real-World" Research helps Biopharma Customers Drive Competitive Advantage

    Press Release — September 19, 2011 –A perfect storm of stakeholder demands, unprecedented data access, new data channels and technologies is driving a dramatic shift in research methodologies among biopharmaceutical companies, according to a new report from Quintiles.

  • A Focus on CNS

    Brochure — July 1, 2011
    Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process.

  • KoNECT & Quintiles Partner to Advance Clinical Research

    Press Release — May 30, 2011 – The Korea National Enterprise for Clinical Trials (KoNECT) and Quintiles have partnered to produce educational events in South Korea for investigators and biopharmaceutical companies.

  • Clinical – Smarter Trials, Accelerated Outcomes

    Brochure — February 16, 2011
    Quintiles will work with you to plan and execute the smartest clinical trials and post-marketing studies, informed by a holistic view of strategic, operational, regulatory and marketplace issues.

  • With so many CROs out there, which one is the best?

    Media Coverage — June 5, 2009
    PharmaceuticalJobSite.com decided "to try and determine which is the best CRO....we have decided on which CRO we feel has the best overall reputation."

  • Badania Kliniczne

    Brochure — April 10, 2009
    Quintiles Poland świadczy usługi związane z organizacją i monitorowaniem Badań Klinicznych faz I-IV. Każdy nowy lek - zanim będzie dostępny w sprzedaży- musi przejść fazę wszechstronnych, specjalistycznych testów i uzyskać aprobatę organów rejestracyjnych.

  • Antibiotic Safety Assessment

    Case Study — March 25, 2009
    A major pharmaceutical company presented Quintiles with a pressing challenge – to collect extensive amounts of Phase IV data in compressed time windows because the treatment conditions were subject to seasonal variants.

Page 1 of 1 (8 results)

Subscribe to Email Based on Your Interests

Set preferences